These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17502830)

  • 21. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis.
    Hughes LB; Beasley TM; Patel H; Tiwari HK; Morgan SL; Baggott JE; Saag KG; McNicholl J; Moreland LW; Alarcón GS; Bridges SL
    Ann Rheum Dis; 2006 Sep; 65(9):1213-8. PubMed ID: 16439441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacogenetics of methotrexate.
    Hider SL; Bruce IN; Thomson W
    Rheumatology (Oxford); 2007 Oct; 46(10):1520-4. PubMed ID: 17586865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Race and methotrexate pharmacogenetics in rheumatoid arthritis.
    Ranganathan P; McLeod H
    J Rheumatol; 2010 May; 37(5):1064; author reply 1065. PubMed ID: 20439524
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis.
    Plaza-Plaza JC; Aguilera M; Cañadas-Garre M; Chemello C; González-Utrilla A; Faus Dader MJ; Calleja MA
    OMICS; 2012 Nov; 16(11):589-95. PubMed ID: 23095111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.
    Wessels JA; Kooloos WM; De Jonge R; De Vries-Bouwstra JK; Allaart CF; Linssen A; Collee G; De Sonnaville P; Lindemans J; Huizinga TW; Guchelaar HJ
    Arthritis Rheum; 2006 Sep; 54(9):2830-9. PubMed ID: 16947783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate.
    Stamp LK; Chapman PT; O'Donnell JL; Zhang M; James J; Frampton C; Barclay ML; Kennedy MA; Roberts RL
    Pharmacogenet Genomics; 2010 Jun; 20(6):367-76. PubMed ID: 20386493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses.
    Urano W; Taniguchi A; Yamanaka H; Tanaka E; Nakajima H; Matsuda Y; Akama H; Kitamura Y; Kamatani N
    Pharmacogenetics; 2002 Apr; 12(3):183-90. PubMed ID: 11927833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylene tetrahydrofolate reductase genotypes frequencies: association with toxicity and response to methotrexate in rheumatoid arthritis patients.
    Saleh MM; Irshaid YM; Mustafa KN
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):154-62. PubMed ID: 25492850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.
    Lee YH; Song GG
    Clin Drug Investig; 2010; 30(2):101-8. PubMed ID: 20067328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of association between MTHFR A1298C polymorphism and outcome of methotrexate treatment in rheumatoid arthritis patients: evidence from a systematic review and meta-analysis.
    Fan H; Li Y; Zhang L; Li Y; Li W
    Int J Rheum Dis; 2017 May; 20(5):526-540. PubMed ID: 28544525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients.
    Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
    Clin Exp Rheumatol; 2009; 27(3):499-502. PubMed ID: 19604445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis].
    Taniguchi A; Urano W; Tanaka E; Kamatani N
    Nihon Rinsho; 2007 Feb; 65(2):371-9. PubMed ID: 17302286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway.
    Chaabane S; Marzouk S; Akrout R; Ben Hamad M; Achour Y; Rebai A; Keskes L; Fourati H; Bahloul Z; Maalej A
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):385-93. PubMed ID: 26077125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
    Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ
    Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimalization of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond.
    Kooloos WM; Wessels JA; van der Kooij SM; Allaart CF; Huizinga TW; Guchelaar HJ
    Ann Rheum Dis; 2009 Aug; 68(8):1371. PubMed ID: 19605746
    [No Abstract]   [Full Text] [Related]  

  • 40. Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis.
    Choe JY; Lee H; Jung HY; Park SH; Bae SC; Kim SK
    Rheumatol Int; 2012 Jun; 32(6):1837-42. PubMed ID: 21773884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.